Intraocular pressure-reducing effects and safety of latanoprost versus timolol in patients with chronic angle-closure glaucoma

Ophthalmology

Volumn 111, Issue 3, 2004, Pages 427-434

  Chew, Paul T K ^a   Aung, Tin ^b   Aquino, M V ^c   Rojanapongpun, Prin ^d  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b SINGAPORE NATIONAL EYE CENTRE   (Singapore)

^c UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^d CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

LATANOPROST; TIMOLOL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; CONFIDENCE INTERVAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG SAFETY; EYE DISEASE; EYE IRRITATION; EYE PAIN; FEMALE; FILAMENT KERATITIS; HEADACHE; HUMAN; INSOMNIA; INTRAOCULAR PRESSURE; KERATITIC PRECIPITATE; KERATITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS OF COVARIANCE; PRIORITY JOURNAL; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SIDE EFFECT; SUPERFICIAL PUNCTATE KERATITIS; TREATMENT OUTCOME; VISUAL IMPAIRMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CHRONIC DISEASE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLAUCOMA, ANGLE-CLOSURE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; PROSTAGLANDINS F, SYNTHETIC; TIMOLOL;

EID: 1442275276     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2003.06.007     Document Type: Article

References (28)

1. Thylefors B., Negrel A.D., Pararajasegaram R., Dadzie K.Y. Global data on blindness. Bull World Health Organ. 73:1995;115-121.
2. Lowe R.F., Ritch R. Angle-closure glaucoma mechanisms and epidemiology. Ritch R., Shields M.B., Krupin T. The Glaucomas. 2nd ed:1996;801-819 C.V. Mosby, St. Louis.
3. Lowe R.F., Ritch R. Angle-closure glaucoma clinical types. Ritch R., Shields M.B., Krupin T. The Glaucomas. 2nd ed :1996;821-840 C.V. Mosby, St. Louis.
4. Aung T., Wong H.T., Yip C.C., et al. Comparison of the intraocular pressure-lowering effect of latanoprost and timolol in patients with chronic angle closure glaucoma a preliminary study. Ophthalmology. 107:2000;1178-1183.
5. Hotehama Y., Mishima H.K. Clinical efficacy of PhXA34 and PhXA41, two novel prostaglandin F2α-isopropyl ester analogues for glaucoma treatment. Jpn J Ophthalmol. 37:1993;259-269.
6. Ziai N., Dolan J.W., Kacere R.D., Brubaker R.F. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2α analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol. 111:1993;1351-1358.
7. Alm A., Villumsen J., Törnquist P., et al. Intraocular pressure-reducing effect of PhXA41 in patients with increased eye pressure a one-month study. Ophthalmology. 100:1993;1312-1316., discussion 1316-7.
8. Nagasubramanian S., Sheth G.P., Hitchings R.A., Stjernschantz J. Intraocular pressure-reducing effect of PhXA41 in ocular hypertension comparison of dose regimens. Ophthalmology. 100:1993;1305-1311.
9. Alm A., Stjernschantz J., Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning a comparison with timolol. Ophthalmology. 102:1995;1743-1752.
10. Camras C.B., United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma a six-month, masked, multicenter trial in the United States. Ophthalmology. 103:1996;138-147.
11. Mishima H.K., Masuda K., Kitazawa Y., et al. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension a 12-week study. Arch Ophthalmol. 114:1996;929-932.
12. Watson P., Stjernschantz J., Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology. 103:1996;126-137.
13. Hedman K., Alm A. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol. 10:2000;95-104.
14. Hung P.T., Hsieh J.W., Chen Y.F., Wei T. Efficacy of latanoprost as an adjunct to medical therapy for residual angle-closure glaucoma after iridectomy. J Ocul Pharmacol Ther. 16:2000;43-47.
15. Kass M.A., Gordon M.O., Hoff M.R., et al. Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals a randomized, double-masked, long-term clinical trial. Arch Ophthalmol. 107:1989;1590-1598.
16. Sommer A., Tielsch J.M., Katz J., et al. Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol. 109:1991;1090-1095.
17. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 126:1998;487-497.
18. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS) 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol. 130:2000;429-440.
19. Kass M.A., Heuer D.K., Higginbotham E.J., et al. The Ocular Hypertension Treatment Study a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 120:2002;701-713.
20. Lazarus H.M., Imperia P.S., Botti R.E., Mack R.J., Lass J.H. An in vitro method which assesses corneal epithelial toxicity due to antineoplastic, preservative and antimicrobial agents. Lens Eye Toxic Res. 6:1989;59-85.
21. Astin M., Stjernschantz J. Mediation of prostaglandin F2α-induced ocular surface hyperemia by sensory nerves in rabbits. Curr Eye Res. 16:1997;886-890.
22. Hoyng P.F., van Beek L.M. Pharmacological therapy for glaucoma a review. Drugs. 59:2000;411-434.
23. Alm A., Widengard I. Latanoprost experience of 2-year treatment in Scandinavia. Acta Ophthalmol Scand. 78:2000;71-76.
24. Chiba T., Kashiwagi K., Kogure S., et al. Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese galucoma patients. J Glaucoma. 10:2001;406-410.
25. Costagliola C., Del Prete A., Verolino M., et al. Effect of 0.005% latanoprost once daily on intraocular pressure in glaucomatous patients not adequately controlled by beta-blockers twice daily a 3-year follow-up. Experience and incidence of side effects in a prospective study on 76 patients. Graefes Arch Clin Exp Ophthalmol. 240:2002;379-386.
26. Martinez-Garcia A., Perez-Garcia R. Efficacy of latanoprost monotherapy treatment in primary open-angle glaucoma. [in Spanish] Arch Soc Esp Oftalmol. 77:2002;269-274.
27. Perfetti S., Varotto A., Massagrandi S., et al. Glaucoma and quality of the life. Acta Ophthalmol Scand Suppl. 227:1998;52.
28. Patel S.C., Spaeth G.L. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 26:1995;233-236.